FilingSEC EDGAR6-K
Clearmind Medicine Submits Recommendations to FDA on Psychedelic Therapies
· SEC accepted
StageClinical-stage
Filing content
Clearmind Medicine submitted recommendations to the FDA regarding the potential future therapeutic use of non-hallucinogenic neuroplastogens in response to the agency's request for comments.
AI summary of the filing. Please also check the source.Related companies
Analyzed by WAPE AI.
Preparing English content…
Comments —
Loading comments…